- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05125809
Undersøgelse for at vurdere dosis, effektivitet og sikkerhed af Setrusumab hos deltagere med osteogenesis imperfecta (Orbit)
Et operationelt sømløst, randomiseret fase 2/3-studie bestående af en fase 2-enkeltblind dosis-evalueringsfase og en fase 3 dobbeltblind, placebokontrolleret fase for at vurdere effektiviteten og sikkerheden af Setrusumab hos personer med osteogenesis imperfecta
The primary objectives of the study are to identify a setrusumab dosing strategy in participants with OI and to evaluate the effect of setrusumab vs placebo on reduction in fracture rate.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
Participants in Phase 2 will be randomized 1:1 to receive low dose or high dose setrusumab. Phase 2 participants will continue receiving their assigned dose of setrusumab until all Phase 2 participants have completed the Month 6 study visit. After this point, Phase 2 participants will begin receiving the selected dosing strategy in the Phase 2 open-label Treatment Extension Period. Phase 3 participants will be randomized 2:1 to receive setrusumab or placebo during the double-blind treatment period. Phase 3 participants will transition to the open-label Treatment Extension Period after the end of the double-blind period. Participants in the Phase 2 and Phase 3 treatment extension periods will receive open-label setrusumab treatment for at least 12 months, and have the option to remain in the open-label treatment period until setrusumab is commercially available in their region. An optional substudy will be conducted in approximately 10 participants (≥ 8 years) consisting of a bone biopsy to investigate the impact of setrusumab on bone histomorphology.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 3
Kontakter og lokationer
Studiesteder
-
-
-
Melbourne, Australien
- Royal Children's Hospital
-
-
Queensland
-
South Brisbane, Queensland, Australien, QLD 4101
- Queensland Paediatric Endocrinology
-
-
-
-
-
Montreal, Canada, H4A 3J1
- McGill University Health Centre
-
Toronto, Canada
- University of Toronto- The Hospital for Sick Children (SickKids)
-
-
Ontario
-
London, Ontario, Canada
- London Health Sciences Center
-
Ottawa, Ontario, Canada, K1H 8L1
- Children's Hospital of Eastern Ontario
-
-
-
-
-
Manchester, Det Forenede Kongerige
- Royal Manchester Childrens Hospital
-
Sheffield, Det Forenede Kongerige, S10 2TH
- Sheffield Children's NHS Foundation Trust
-
-
-
-
Arkansas
-
Little Rock, Arkansas, Forenede Stater, 72202
- Arkansas Children's Hospital
-
-
California
-
Los Angeles, California, Forenede Stater, 90027
- Children's Hospital Los Angeles
-
Sacramento, California, Forenede Stater, 95817
- Shriners Hospital for Children - Northern California
-
-
Colorado
-
Aurora, Colorado, Forenede Stater, 80045
- Children's Hospital Colorado
-
-
Connecticut
-
Hartford, Connecticut, Forenede Stater, 06106
- Connecticut Children's Medical Center
-
New Haven, Connecticut, Forenede Stater, 06510
- Yale New Haven Hospital
-
-
Delaware
-
Wilmington, Delaware, Forenede Stater, 19803
- Nemours/ Alfred i. duPoint Hospital for Children
-
-
District of Columbia
-
Washington D.C., District of Columbia, Forenede Stater, 20010
- Children's National Medical Center
-
-
Florida
-
Tampa, Florida, Forenede Stater, 33612
- University of South Florida
-
-
Illinois
-
Chicago, Illinois, Forenede Stater, 60707
- Shriners Hospitals for Children - Chicago
-
-
Indiana
-
Indianapolis, Indiana, Forenede Stater, 46202
- Indiana University Hospital
-
-
Maryland
-
Baltimore, Maryland, Forenede Stater, 21205
- Kennedy Krieger Institute
-
-
Missouri
-
St Louis, Missouri, Forenede Stater, 63110
- Washington University School of Medicine
-
-
Nebraska
-
Omaha, Nebraska, Forenede Stater, 68114
- Children's Hospital and Medical Center
-
-
New Mexico
-
Albuquerque, New Mexico, Forenede Stater, 87106
- New Mexico Clinical Research & Osteoporosis Center, Inc.
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28203
- Atrium Health Levine Children's Hospital
-
-
Ohio
-
Columbus, Ohio, Forenede Stater, 43205
- Nationwide Children's Hospital- Ohio State University College of Medicine
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Forenede Stater, 19104
- The Children's Hospital of Philadelphia
-
-
Tennessee
-
Nashville, Tennessee, Forenede Stater, 37232
- Vanderbilt University Medical Center
-
-
Texas
-
Fort Worth, Texas, Forenede Stater, 76104
- Cook Children's Medical Center
-
Houston, Texas, Forenede Stater, 77030
- Baylor College of Medicine
-
-
Wisconsin
-
Madison, Wisconsin, Forenede Stater, 53792
- UW Health University Hospital
-
-
-
-
-
Paris, Frankrig
- Institut Imagine
-
-
-
-
-
Utrecht, Holland
- Wilhelmina Children's Hospital
-
-
-
-
-
Bologna, Italien
- Istituto Ortopedico Rizzoli
-
Rome, Italien, 00161
- Azienda Ospedaliera Universitaria Policlinico Umberto I
-
Verona, Italien
- Universita Degli Studi Di Verona
-
-
-
-
-
Lodz, Polen
- Uniwersytet Medyczny w Lodzi - Klinika Endokrynologii i Chorob Metabolicznych
-
-
-
-
-
Lisbon, Portugal, 1649-028
- Hospital de Santa Maria
-
Porto, Portugal, 4099-001
- Centro Hospitalar do Porto
-
-
-
-
-
Ankara, Tyrkiet (Türkiye)
- Gazi University
-
Istanbul, Tyrkiet (Türkiye)
- Marmara University
-
-
-
-
-
Cologne, Tyskland
- University of Cologne
-
Magdeburg, Tyskland, 39106
- Otto von Guericke University Magdeburg
-
Würzburg, Tyskland, 97074
- Musculoskeletal Center Würzburg
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Diagnosis of OI Type I, III, or IV as confirmed by identification of pathogenic or likely pathogenic genetic variants in COL1A1 or COL1A2. If a variant of uncertain significance is identified, then clinical presence of the expected phenotype can be used to confirm the diagnosis
- ≥ 1 fracture in the past 12 months, ≥ 2 fractures in the past 24 months or ≥ 1 tibia, femur or humerus fracture in the past 24 months
- Serum 25-hydroxyvitamin D ≥ 20 ng/mL at the Screening Visit. If 25-hydroxyvitamin D levels are below 20 ng/mL, 25-hydroxyvitamin D testing can repeated after a minimum of 14 days of vitamin D supplementation as directed by the treating physician
- Willing to not receive bisphosphonate therapy during the study
- From the period following informed consent to 60 days after the last dose of the study drug, females of childbearing potential and fertile males must consent to use highly effective contraception. If female, agree not to become pregnant. If male, agree not to father a child or donate sperm
- Willing and able to provide informed consent for subjects greater than or equal to 18 years of age, or provide assent (if possible) and have a legally authorized representative provide informed consent, after the nature of the study has been explained and prior to any research-related procedures
- Willing to provide access to medical records for the collection of radiographic data, fracture data, growth data, and disease history
- Must, in the opinion of the Investigator, be willing and able to complete all aspects of the study, adhere to the study visit schedule, and comply with the assessments
Exclusion Criteria:
-
History of skeletal malignancies or bone metastases at any time
-
History of neural foraminal stenosis (except if due to scoliosis)
-
Clinical manifestations of Chiari malformation or basilar invagination. Presence of any other neurologic disease that has been unstable within past 2 years requires review by the Medical Monitor
-
History of or uncontrolled concomitant diseases such as hypo/hyperparathyroidism, Paget's disease, abnormal thyroid function, thyroid disease or other endocrine disorders or conditions that could affect bone metabolism such as Stage IV/V renal disease
-
Rickets or any skeletal condition (other than OI) leading to long-bone deformities and/or increased risk of fractures
-
History of stroke, myocardial infarction, transient ischemic attack or angina.
-
Hypocalcemia, defined as serum calcium levels below the age-adjusted normal limits after a ≥ 4 hour fast
-
Estimated glomerular filtration rate ≤ 29 mL/min/1.73 m2
-
Prior treatment with the following:
- Teriparatide, growth hormone, bone anabolic, or anti-resorptive medications (other than bisphosphonates) within 6 months of the first dose with study drug (Month 0)
- Denosumab within 24 months of Screening
- Romosozumab at any time
-
Documented alcohol and/or drug abuse within 12 months prior to dosing or evidence of such abuse as indicated by the laboratory results during the Screening assessments
-
Presence or history of any condition that, in the view of the Investigator, would interfere with participation, pose undue risk, or would confound interpretation of results
-
Known hypersensitivity to setrusumab or excipients that, in the judgment of the Investigator, places the subject at increased risk for adverse effects
-
History of external radiation therapy
-
Pregnant or breastfeeding or planning to become pregnant (self or partner) at any time during the study
-
Use of any investigational product or investigational medical device within 4 weeks or 5 half-lives of investigational drug (whichever is longer) prior to Screening, or during the study (per discretion of the Investigator in consultation with the Medical Monitor)
-
Concurrent participation in another clinical study without prior approval from the Investigator in consultation with the Medical Monitor
-
For Phase 2 Only: A history of bone surgery within the previous 6 months prior to Screening or planned bone surgery for the first 3 months of the study
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Low Dose Setrusumab -> Open-Label (OL) Setrusumab Selected Dose
Single-blind setrusumab low dose during Phase 2 followed by open-label setrusumab selected dose During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician |
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Andre navne:
|
|
Eksperimentel: High Dose Setrusumab -> OL Setrusumab Selected Dose
Single-blind setrusumab high dose during Phase 2 followed by open-label setrusumab During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician |
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Andre navne:
|
|
Eksperimentel: Setrusumab Selected Dose -> OL Setrusumab Selected Dose
Double-blind setrusumab selected dose during Phase 3 followed by open-label setrusumab During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician |
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Andre navne:
|
|
Placebo komparator: Placebo -> OL Setrusumab Selected Dose
Double-blind placebo during Phase 3 followed by open-label setrusumab During treatment and treatment extension periods, participants may receive supplementation with calcium and vitamin D to maintain normal values as directed by the treating physician |
A fully human sclerostin neutralizing monoclonal antibody (mAb) administered once a month (QM) via intravenous (IV) infusion
Andre navne:
A 5% dextrose/glucose solution administered QM via IV infusion |
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Fase 2: Procent ændring i serum aminoterminalt propeptid af type 1 procollagen (P1NP) fra baseline ved 1. måned
Tidsramme: Baseline, måned 1
|
Baseline, måned 1
|
|
Fase 3: Årlig hastighed for alle radiografiske bekræftede brud, eksklusive morfometriske rygsøjlefrakturer og brud på fingrene, tæerne, ansigt og kranium ved den primære analyse
Tidsramme: Op til måned 24
|
Op til måned 24
|
Sekundære resultatmål
Resultatmål |
Tidsramme |
|---|---|
|
Fase 2: Serum Setrusumab Koncentration
Tidsramme: Fra foruddosis op til måned 24
|
Fra foruddosis op til måned 24
|
|
Fase 2: Baseline-korrigeret område under effektkurven (AUEC) for serum P1NP over en 1 og 2-måneders periode
Tidsramme: Baseline, op til måned 2
|
Baseline, op til måned 2
|
|
Fase 2: Procent ændring fra baseline over tid i knogleomsætningsmarkør: P1NP
Tidsramme: Baseline, op til måned 24
|
Baseline, op til måned 24
|
|
Fase 2: Procentvis ændring fra baseline over tid i knogleomsætningsmarkør: Osteocalcin (OCN)
Tidsramme: Baseline, op til måned 24
|
Baseline, op til måned 24
|
|
Fase 2: Ændring fra baseline i Dual Energy X-ray (DXA) Lumbal Spine Bone Mineral Density (BMD) Z-score over tid
Tidsramme: Baseline, op til måned 24
|
Baseline, op til måned 24
|
|
Fase 2: Procentvis ændring fra baseline i DXA Lumbal Spine BMD over tid
Tidsramme: Baseline, op til måned 24
|
Baseline, op til måned 24
|
|
Fase 2: Antal deltagere med behandling Emergent Adverse Events (TEAE'er), Serious Adverse Events (SAE'er) og Adverse Events of Special Interest (AESI'er)
Tidsramme: Op til måned 24
|
Op til måned 24
|
|
Fase 3: Antal deltagere med behandling Emergent Adverse Events (TEAE'er), Serious Adverse Events (SAE'er) og Adverse Events of Special Interest (AESI'er)
Tidsramme: Op til måned 24
|
Op til måned 24
|
|
Fase 2: Antal deltagere med anti-Setrusumab bindende og neutraliserende antistoffer
Tidsramme: Op til måned 24
|
Op til måned 24
|
|
Fase 3: Antal deltagere med anti-Setrusumab bindende og neutraliserende antistoffer
Tidsramme: Op til måned 24
|
Op til måned 24
|
|
Fase 3: Årlig hastighed for alle radiografisk bekræftede brud, eksklusive morfometriske rygsøjlefrakturer, men inklusive brud på fingrene, tæerne, ansigt og kranium ved den primære analyse
Tidsramme: Op til måned 24
|
Op til måned 24
|
|
Fase 3: Årlig sats for alle radiografiske bekræftede brud ved den primære analyse
Tidsramme: Op til måned 24
|
Op til måned 24
|
|
Fase 3: Skift fra baseline i DXA Lumber Spine BMD Z-score ved den primære analyse
Tidsramme: Baseline, op til måned 24
|
Baseline, op til måned 24
|
|
Fase 3: Skift fra baseline i pædiatrisk ortopædisk samfund i Nordamerika Pædiatriske resultater Dataindsamlingsinstrument (POSNA-PODCI) Sports/fysisk funktionsunderskala score for pædiatriske deltagere ved den primære analyse
Tidsramme: Baseline, op til måned 24
|
Baseline, op til måned 24
|
|
Fase 3: Andel af deltagere, der oplever nye radiografisk bekræftede brud, eksklusive morfometriske rygsøjlefrakturer og brud på fingrene, tæerne, ansigt og kranium ved den primære analyse
Tidsramme: Op til måned 24
|
Op til måned 24
|
|
Fase 3: Skift fra baseline i Posna-Podci Pain/Comfort-underskala score for pædiatriske deltagere ved den primære analyse
Tidsramme: Baseline, op til måned 24
|
Baseline, op til måned 24
|
|
Fase 3: Skift fra baseline i 36-varer kort form for sundhedsundersøgelse (SF-36) Fysisk funktionsdomæneskala for voksne deltagere ved den primære analyse
Tidsramme: Baseline, op til måned 24
|
Baseline, op til måned 24
|
|
Fase 3: Skift fra baseline i SF-36 kropslig smerte (BP) domæneskala for voksne deltagere ved den primære analyse
Tidsramme: Baseline, op til måned 24
|
Baseline, op til måned 24
|
Samarbejdspartnere og efterforskere
Sponsor
Samarbejdspartnere
Efterforskere
- Studieleder: Ultragenyx Medical Director, Ultragenyx Pharmaceutical Inc
Publikationer og nyttige links
Generelle publikationer
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Yderligere relevante MeSH-vilkår
Andre undersøgelses-id-numre
- UX143-CL301
- 2021-006597-23 (EudraCT nummer)
- 2024-510919-29-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .